Ciclosporin/Lansoprazole

环孢素/兰索拉唑

Report date: 2026/01/21 17:07:05

Base Information

Drug NameCiclosporin/Lansoprazole
Drug Alias Name环孢素+兰索拉唑Lansoprazole/CyclosporineCyclosporine/LansoprazoleLansoprazole+CiclosporinCiclosporin+Lansoprazole +[6] 
ClassificationSmall molecules > Molecular GlueSmall molecules > Heterocyclic drugs
Mechanisms of ActionProton pump inhibitorsCalcineurin inhibitorsMitocliondrial permeability transition pore inhibitors +[5] 
TargetsProton pumpCalcineurinMitocliondrial permeability transition pore +[4] 
Therapy Area/IndicationsDiabetes Mellitus, Type 1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes LansoprazoleCyclosporine
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPerle Bioscience Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPerle Bioscience Inc
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 1

Other Information

ATC CodeN/A
Related LinksN/A